1. Introduction {#s0005}
===============

The evaluation of biomarkers for the early diagnosis of neurodegenerative conditions causing dementia has been increasingly recognized as of outmost importance in research and clinical practice ([@bb0005]; [@bb0010]; [@bb0020]; [@bb0075]; [@bb0090]; [@bb0130]; [@bb0135]; [@bb0180]; [@bb0220]). As for Alzheimer\'s Disease (AD), the development of Positron Emission Tomography (PET) techniques to investigate brain amyloid accumulation (amyloid-PET) brought landmark changes in clinical neuroscience research ([@bb0265]). The reliability of PET tracers for in vivo amyloid assessment is supported by their correlation with post-mortem amyloid plaque measurement ([@bb0070]; [@bb0195]; [@bb0280]).

To date, their mandatory adoption in clinical trials and the great potential for diagnostic purposes is recognized, in particular to rule out AD pathology ([@bb0260]; [@bb0255]). Amyloid PET imaging plays a fundamental role for the inclusion and exclusion of subjects in clinical trials based on anti-amyloid treatments ([@bb0225], [@bb0230]), and it has been used as an outcome measure as well ([@bb0205]; [@bb0215]). The positivity of an amyloid-PET scan is commonly assessed qualitatively through a visual evaluation of the PET radiotracer distribution, in accordance to tracer-specific guidelines ([@bb0185]).

A correct and reliable quantification of regional amyloid burden with PET, however, is considered mandatory to avoid the limitations of the operator-dependent visual classification, especially in longitudinal studies ([@bb0170], [@bb0175]). The most commonly adopted semi-quantification techniques involve tracer-specific approaches to estimate regional amyloid burden based on Standardized Uptake Value Ratio (SUVr) measurements. SUVrs are obtained by comparing tracer uptake in target regions to a reference area devoid of specific uptake. By comparing SUVrs in AD patients with SUVrs obtained in healthy volunteers, previous studies derived cut-off thresholds that could discriminate between amyloid positive and amyloid negative individuals ([@bb0030]; [@bb0065]; [@bb0080]; [@bb0145]; [@bb0150]; [@bb0160]; [@bb0250]). Semi-quantitative amyloid burden is generally estimated on average (composite) SUVr based on neocortical regions, usually including frontal, parietal, temporal and cingulate regions ([@bb0070]; [@bb0080]). The adopted reference regions for amyloid PET SUVr can vary and may include the whole cerebellum, the cerebellar gray matter (GM) and/or specific portions of the white matter (WM) ([@bb0040]; [@bb0210]). Of note, the implementation of semi-quantification techniques can also introduce variability, especially with respect to differences in analysis procedures and scan protocols. All these factors can heavily impact the classification of amyloid burden, with considerable effects in research studies and consequences in clinical trials (e.g. inclusion/exclusion of subjects). Among the most important factors there are: i) the selection of regions of interest (ROIs); ii) the selection of reference regions and iii) the choice of running quantifications in either native or standard space, with the latter being strongly influenced by the spatial normalization algorithms.

In an ideal setting, structural Magnetic Resonance Imaging (MRI) scans are available for each subject, allowing high precision spatial normalization and ROIs definition. Conveying the PET images to standard space can offer the use of standardized, published atlases with regions of interest, such as Automatic Anatomical Labeling: AAL ([@bb0245]), Talairach Daemon: TD ([@bb0110]; [@bb0105]), Individual Brain Atlas: IBA ([@bb0015]), allowing for the definition of ROIs and to estimate regional SUVrs. In a routine diagnostic setting, however, MRI data are not always available, thus preventing an MRI-based spatial normalization of the amyloid-PET images to a standard space. For many centers, the lack of an MRI-based normalization pipeline prevents any further quantification.

To overcome this limitation, several PET-only pipelines for spatial normalization have been developed, based on custom or simulated PET templates ([@bb0085]; [@bb0115]; [@bb0200]). These templates enable an accurate PET image warping and semi-quantification, but they are tracer-specific, limiting their utilization to radioligands with similar radioactivity distributions. Furthermore, to perform an appropriate PET-based normalization, the tracer uptake should define brain anatomy in sufficient details, which is not always the case for PET molecular imaging radiotracers. Finally, the spatial distribution of the tracer should be reasonably similar across subjects, to prevent bias in registration. This is not the case for amyloid tracers, where tracer distribution varies markedly across individuals, depending on the degree of amyloid burden: while in positive cases GM uptake is on par with WM uptake, amyloid-negative subjects display high contrast between the two.

Building on these premises, there is a need for validated methods to perform reliable spatial normalization of PET amyloid images. In this view, and considering that most PET clinical studies are nowadays performed using PET/Computed Tomography (CT) systems, we tested and validated a method for a high precision spatial normalization and SUVr computation using the low-dose CT image acquired for attenuation correction (AC). The inclusion of a CT-based analytical pipeline for PET quantification would allow a net benefit in terms of both research and clinical practice, allowing the recruitment of larger samples and favoring clinical routine analysis.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

Subjects were retrieved from the Ricerca Finalizzata Progetto di Rete Nazionale AD (AD-NETWORK/RETEAD) database. RETEAD is a large Italian multicenter study that aims at developing and validating operational research criteria for diagnosis of AD in the preclinical/predementia phase and early recognition of atypical forms, based on a multi-factorial protocol that integrates molecular, imaging, neuropsychological and clinical profiles. The study conformed to the ethical standards of the Declaration of Helsinki for protection of human subjects. Each subject provided written informed consent as approved by the Local Ethical Committees.

Thirty four subjects (age = 69.58 ± 6.63 (range:50--80) years; M/F = 16/18) were recruited at Fondazione IRCCS Istituto Neurologico Besta, Milan. The sample consisted of subjects in preclinical and prodromal dementia phases and patients with overt dementia, thus covering a wide spectrum of cases, from normal cognition to dementia. In detail, the sample included 4 subjects with subjective cognitive complaints ([@bb0100]), 12 subjects with pre-mild cognitive impairment (pre-MCI) ([@bb0235]), 14 subjects with MCI (8 single-domain MCI and 6 multi-domain MCI) ([@bb0140]) and 4 patients with a diagnosis of probable AD dementia ([@bb0135]). Each subject underwent brain structural imaging, including an MRI scan at Fondazione IRCCS Istituto Neurologico Besta, Milan and an amyloid PET/CT scan at the Nuclear Medicine Unit of San Raffaele Hospital, Milan. Inter-scan interval was no longer than six months for MRI and amyloid PET scans.

2.2. Image acquisition {#s0020}
----------------------

### 2.2.1. ^18^F-Florbetaben PET/CT {#s0025}

Each subject received an intravenous injection of 300 ± − 37 MBq of ^18^F-Florbetaben (Neuraceq, Piramal). The dose was administered as a single bolus injection followed by 20 cc of saline flush. All PET acquisition were performed using a hybrid PET/CT Discovery-690 system (General Electric Medical Systems Milwaukee, WI, USA) ([@bb0035]). After positioning, a low dose CT scan (kVp: 140 kV, current: 40 mA, rotation time: 0.8 s, slice thickness: 3.75 mm, pitch: 1.375:1) was acquired to be used for attenuation correction of PET data. Images were reconstructed using the "standard" kernel, a 30 cm reconstruction field of view, and 3.27 mm slice interval, for a resulting voxel size of 0.59 × 0.59 × 3.27 mm^3^. A 3D-PET acquisition (list mode) was started about 90 min after the injection of the tracer and lasted for 20 min. Image reconstruction was performed by using a 3D Ordered Subsets Expectation Maximization (OSEM) algorithm with the following parameters: Image matrix = 128, Field Of View = 250 mm, Subsets = 24, Iterations = 3, Post Filter (Gaussian) = 3 mm FWHM, Attenuation Correction = CT-based. The resulting voxel size was 1.95 × 1.95 × 3.27 mm^3^.

### 2.2.2. MRI {#s0030}

The MRI imaging data were acquired in Neurological Institute "C. Besta", using an Achieva 3 T MR scanner (Philips Healthcare BV, Best, NL) equipped with a 32-channel head coil. A volumetric turbo field echo (TFE) T1-weighted structural sequence (180 sagittal slices, TR = 8.3 ms, TE = 3.9 ms, FOV = 240 × 240 mm, voxel size = 1x1x1 mm^3^, flip angle = 8°) was acquired for each subject. Other structural, diffusion and functional magnetic imaging data were also collected in the same session, but not reported in this study. The total duration of scanning session was around 55 min.

### 2.2.3. Image processing {#s0040}

All CT and MRI images were converted from the original DICOM to a NIFTI format using SPM12. The origin coordinates of the MRI scan were manually set to the anterior commissure. CT and PET images were rigidly co-registered to the respective MRI scan. A visual inspection was always performed as a quality control to detect possible errors in the co-registration step.

2.3. Spatial normalization {#s0045}
--------------------------

### 2.3.1. CT-based normalization algorithm {#s0050}

The hypothesis of the proposed procedure is that a low dose CT scan contains enough information in terms of contrast between GM, WM and cerebro-spinal fluid (CSF) to estimate the spatial transformation accurately. To spatially normalize the CT images into the stereotactic/standard space, we optimized the unified segmentation-normalization algorithm as implemented by Ashburner and Friston in SPM12 ([@bb0025]). This algorithm iteratively finds the spatial transformation that best matches the analyzed image to a set of tissue probability maps (TPM), that are used in a subsequent tissue classification procedure.

The algorithm works with a parametrization of the image intensities for each tissue type using a Gaussian Mixture Model (GMM). In the latest version, known as "new segment", included in SPM12 ([@bb0125]; [@bb0275]), 6 tissue classes are considered: GM, WM, CSF, bone, outside tissues and air. A priori TPM are used to improve the segmentation, to fix initial intensities for each tissue class and to distinguish tissues with identical average intensities. This iterative algorithm first estimates the spatial deformation from the Montreal Neurological Institute (MNI) space to the subject native space. The TPM are then transformed to the subject native space using this deformation and they are used to update the GMM describing the intensities of all tissues. Finally, the spatial transformation from the MNI space to the native space is updated, looking for the one that best matches the current GMM. The procedure is iterated until the algorithm converges. Forward and backward transformations are both estimated.

In our proposed optimization, the CT images are pre-processed by a "clean-up" procedure. Every value lower than −300 HU is set to −1024 HU, to avoid low-density structures outside the head (e.g.: head-holder, cushion etc.) confounding the algorithm. Without this procedure, the coarse affine registration performed before the actual segmentation often fails. The resulting images are then loaded in the SPM12 unified segmentation algorithm, with optimized parameters. Compared to the default SPM12 settings for MRI, we disabled bias-field correction, as CT does not suffer from this artifact. Also, as Hounsfield values are generally comprised in a fixed and narrow range in CT, we used only 1 Gaussian for the GMM of GM, WM, and only 2 Gaussians for the other 4 classes (CSF, bone, outside tissue and air). Identical regularization strengths to the default were used. All the parameters used are summarized in [Table 1](#t0005){ref-type="table"}. The number of Gaussians was chosen a priori, knowing that in CT GM and WM have only one average intensity. For CSF, 2 Gaussians were used to take into account the possibility that CSF close to the bone has higher intensity than that in the ventricles due to spillover effect. As bone has values in a very broad range in CT, 2 gaussians were used. Tissue can be thought as composed of low-intensity fat and higher-intensity areas like muscles, so 2 gaussians also were used. In the "air" class we expect all low intensity structures that have the same value of −1024, after our thresholding, modeled with 1 gaussian, and another Gaussian to model all the other low intensity pixels between about −50 to −300 HU.Table 1Settings for the unified segmentation algorith.Table 1SettingParameterCTMRI\
(default SPM settings)Bias Field CorrectionFWHMDisabled60 mmRegularizationLightTissue GMM: Number of GaussiansGM11WM11CSF22Bone23Tissue24Air22Warping regularizationAbsolute displacement00Membrane Energy0.0010.001Bending Energy0.50.5Linear Elasticity 10.050.05Linear Elasticity 20.20.2

The robustness of our algorithm to different settings was tested in supplementary material.

### 2.3.2. MRI-based spatial normalization {#s0055}

MRI images were spatially normalized to the MNI space using the SPM12 unified segmentation and default settings. The parameters are reported in [Table 1](#t0005){ref-type="table"}, to be compared to the optimization introduced for the CT version. The segmented tissues and the forward transformation to the MNI space are then saved. The spatial transformation was used as a comparison with the CT one. The GM map was also used in a later stage to compare and validate the proposed method (see below).

2.4. Comparison of the CT and MRI normalizations {#s0060}
------------------------------------------------

Two strategies were used to compare the output of the normalization procedures, with the MRI-based normalization considered as the gold standard for the pre-processing step. First, we measured, from the two normalized CT- (nPET~CT~) and MRI-based (nPET~MRI~) ^18^F-Florbetaben PET images, the SUVr values in a set of ROIs commonly considered to estimate amyloid burden in AD. The second strategy consisted in measuring, for each subject, the degree of overlap between the two estimated GM maps (GM~CT~ and GM~MRI~) obtained with the CT- and the MRI-derived transformations. Normalized ^18^F-Florbetaben PET images were resampled to a bounding box of \[−90--126 -72; 90 90,108\] mm with an isotropic voxel size of 2 mm, using the two previously estimated deformations.

### 2.4.1. ^18^F-Florbetaben SUVr estimation {#s0065}

Multiple ROIs for regional and global amyloid burden assessment were selected according to previous literature ([@bb0030]; [@bb0155]; [@bb0195]; [@bb0240]) To summarize, we extracted six ROIs representing wide, bilateral cortical macroareas ([Fig. 1](#f0005){ref-type="fig"}), i.e. Dorsolateral and Medial Frontal Cortex, Cingulum, Precuneus, Inferior and Superior Parietal Lobules, Lateral Occipital Cortex, and Lateral Temporal Cortex, from the Automated Anatomical Labeling (AAL) atlas ([@bb0245]), through the Wake Forest University PickAtlas toolbox for SPM ([@bb0120]). All the images were scaled to the activity of the cerebellar GM, used as the reference region ([@bb0060]; [@bb0270]). The average computed from the six ROIs was considered as an index of global cortical amyloid burden.Fig. 1Visualization of the regions of interest used for the analysis, overlaid on a standardized template.Fig. 1

### 2.4.2. Statistical analysis {#s0070}

Concordance between the SUVr measures was assessed using Bland-Altman plots and estimation of region-wise Pearson correlation analysis. Regional and global amyloid burdens and standard deviations were computed with mean absolute differences and limits of agreement (see [Table 2](#t0010){ref-type="table"}).Table 2Regional and global amyloid SUVr.Table 2ROICT-basedMRI-basedAbsolute DifferenceLimits of AgreementFrontal cortex1.251.280.030−0.125 \| 0.066Cingulum1.391.440.044−0.110 \| 0.022Precuneus1.391.420.026−0.099 \| 0.047Temporal cortex1.341.350.010−0.079 \| 0.056Occipital cortex1.441.400.048−0.067 \| 0.160Parietal cortex1.251.260.011−0.087 \| 0.064Whole cortical regions1.341.350.012−0.075 \| 0.051[^1]

### 2.4.3. Comparison of gray matter maps {#s0075}

The GM maps obtained from the MRI segmentation of each patient were resampled to the MNI space within a bounding box of \[−90--126 -72; 90 90,108\] with an isotropic voxel size of 1 mm, to better capture the limited thickness of GM. The MRI and the CT derived deformations were used to obtain a GM~MRI~ and a GM~CT~ map for each subject. It is reasonable to expect a complete overlap of the two maps in the case of identical deformations. Therefore, we measured the percentage of voxels in the GM~CT~ that overlap with those in the GM~MRI~. The GM~MRI~ was then dilated to the 6 nearest-neighbor voxels in three dimensions, and this dilated map was used again as a reference to perform the same computation. This allowed the assessment of the fraction of GM that was transformed either to the correct location or to a 1 mm wide neighborhood. This dilation was performed two more times to measure concordance within 2 mm and 3 mm wide from the reference. These overlap measures were computed over the whole image and also locally, inside the same ROIs defined for the SUVr analysis.

3. Results {#s0080}
==========

3.1. ^18^F-Florbetaben SUVr {#s0085}
---------------------------

The main steps of the proposed procedure are shown in [Fig. 2](#f0010){ref-type="fig"}. The mean regional SUVr~CT~ and SUVr~MRI~ as well as the composite cortical values are reported in [Table 2](#t0010){ref-type="table"}. Negligible differences were found at regional level. Occipital SUVr scores showed some deviation, but were still negligible (mean absolute difference 0.048, limits of agreement −0.067 \| 0.160), whereas the temporal SUVr scores showed the best concordance (mean absolute difference 0.010, limits of agreement −0.079 \| 0.056). When compared to the regional SUVr~MRI~, the SUVr~CT~ was slightly underestimated for all regions, except for the occipital region which showed the opposite trend. Global amyloid burden showed very narrow differences using average regional SUVr~CT~ or SUVr~MRI~ (mean ± sd 0.012 ± 0.032), as further confirmed by the Bland-Altman plot ([Fig. 3](#f0015){ref-type="fig"}) and correlation analysis (Pearson *r* = 0.994, *p* \< 2.2e-16) ([Fig. 3](#f0015){ref-type="fig"}). In the Bland-Altman plot of the global SURr, we performed a Spearman correlation to test whether there was a trend between the SUVr~CT~ vs SUVr~MRI~ difference and the global SUVr load. There was a trend with ρ^2^ = 0.16, which is significant with *p* = .02.Fig. 2Images of the normalization methods in a representative patient. Left: CT based normalization, Right: MRI based normalization. Top: Native Space structural images; Middle: normalized structural images; Bottom: Amyloid Images normalized with the respective pipelines. MNI: Montreal Neurological Institute.Fig. 2Fig. 3Left: Bland-Altman Plot showing the agreement between the two normalization procedures when quantifying the whole cortical SUVr. Subjects are color coded by their initial diagnosis. Right: Scatter plot showing the correlation between whole cortical SUVr scores obtained using the two procedures. Blue diagonal line represents the identity (y = x) line.Fig. 3

In supplementary materials we show that these results are affected by the exact algorithms settings, at least when using reasonable parameters.

3.2. Comparison of gray matter maps {#s0090}
-----------------------------------

The overlap between GM maps obtained using the two different transformations is shown in [Fig. 4](#f0020){ref-type="fig"}. Transforming the GM maps using the CT-based normalization algorithm provided a 70% overlap with those obtained with MR-based normalization. Notably, \>90% of the GM map voxels from the CT-based normalization were within 1 mm from the MR-transformed ones. Full results including 2 and 3 mm dilation are reported in [Table 3](#t0015){ref-type="table"}.Fig. 4Gray matter segmentation of a representative patient, transformed to the MNI space. Top: CT-based deformation, bottom: MR-based deformation. A contour was drawn on the bottom-row images and applied to the top row, to facilitate comparison.Fig. 4Table 3Gray matter maps overlap.Table 3ROISearch rangeVoxel1 mm2 mm3 mm\[%\]\[%\]\[%\]\[%\]Frontal cortex66889698.7Cingulum76939899.6Precuneus68909799.1Temporal cortex73929899.6Occipital cortex66909799.1Parietal cortex59859598.1Cerebellum85969999.7Whole cortical regions70909798.9[^2]

4. Discussion {#s0095}
=============

A correct AD diagnosis in early prodromal, and even preclinical, disease stages is important, especially for the appropriate inclusion of patients in clinical trials ([@bb0225], [@bb0230]). In this framework, amyloid-PET is unique for the detection of pathological Aβ accumulation in vivo ([@bb0255], [@bb0260]). Amyloid positivity, as shown by PET studies, is currently considered as a supportive biomarker for AD diagnosis according to the diagnostic criteria ([@bb0010]; [@bb0075]; [@bb0135]; [@bb0220]). Validated and standardized amyloid (semi)quantification procedures are therefore needed to overcome the limitations of visual ratings and/or binary classifications, for both diagnostic and research purposes ([@bb0175]), and also for a better evaluation of cases for clinical trials. To this end, there is a need to develop highly reliable (semi)quantification approaches to accurately measure amyloid burden in different brain regions at the single-subject level. Previous studies have focused on how to optimize Amyloid-PET analysis to improve both quantification ([@bb0045]; [@bb0200]) and reliability of longitudinal PET assessments ([@bb0040]; [@bb0050]). Notably, semi-quantification with SUVr increased the classification accuracy in comparison to visual ratings ([@bb0045]; [@bb0055]; [@bb0175]).

The majority of previous studies has focused on the development of highly accurate processing steps for the quantification, especially considering reference and target region selection and definition of optimal scanning protocols. The present study, however, focuses on the preprocessing phase, with the aim of validating a feasible CT-based pipeline which could greatly increase the implementation of semi-quantification protocols in research and clinical settings.

When performing PET data analysis in standard space, spatial normalization is the first and a crucial step for the accurate estimation of radioligand specific uptake. High-precision spatial alignment of brain structures is indeed fundamental to achieve the highest statistical power. High resolution MRI images are currently considered the gold standard for spatial warping and many algorithms are available to compute the individual spatial transformations. MRI scans require extra costs and time, on top of being a procedure that cannot be performed on all patients (e.g. in presence of metallic inserts, or due to claustrophobia). While these limitations might not be relevant in research settings, MRI scans are not always acquired in routine studies in clinical settings.

The CT acquisition protocol resulted in a volumetric CT Dose Index (CTDI~vol~) of about 1.5 mGy, which translated to a Dose Length Product (DLP) of about 25 mGy\*cm, meaning, in an average patient, a dose of \<70 μSv. This dose provides sufficient anatomical details while being extremely low. In this work CT were acquired using 40 mA current and 0.8 s rotation time. The most recent scanners, like ours, can be set up to acquire images with currents as low as 10 mA and lower rotation times, for even lower doses. However, not only the image quality significantly decreases, but also there is the risk of "photon starvation" artefacts, which lead to incorrect attenuation correction ([@bb0285]). To overcome this limit, new methods are being used where the current is not lowered but the number of projections acquired is reduced, using then sparse view reconstruction techniques ([@bb0190]). However, these techniques have only been recently introduced clinically and they have not been optimized to provide anatomical detail.

A limit of this study is that the influence of CT image quality on the algorithm could not be studied. Future studies will need to assess both the lower dose limit at which the algorithm still performs correctly, and also whether the use of diagnostic quality CT provides improvements.

Here we found high concordance with MRI-based normalization using the CT-based normalization procedure. Notably, considering the SUVr values, the standard deviation of the differences between the reference MRI-based normalization and the proposed algorithm was \<0.05 in all the considered ROIs. Therefore, this semi-quantitative approach allowed for an accurate measurement of the amyloid burden in each ROI, which is of importance since regional variations of amyloid burden are well-documented in literature ([@bb0095]; [@bb0165]). Additionally, in the second validation test, comparing the CT- and MRI-based GM maps registration, we found that the maps overlapped within 1 mm in 90% of the voxels. This validation was run on a patient population that spanned over a wide range of pathological stages and of amyloid burden, where brain anatomy might differ due to increased atrophy. Accordingly, global amyloid SUVr for our population ranged from 0.9 to 1.8 SUVr. A very small trend, ρ^2^ = 0.16, was noted in the Bland-Altman plot. Considering that the *p*-value was at the threshold for statistical significance (*p* = .02), this result might be due to the presence of few outliers. Studying this algorithm on larger number of subjects, especially AD with high amyloid load and high levels of atrophy, could further certify the good performance of this algorithm in all the possible conditions. In Supplementary Materials, we have also shown that the algorithm is robust to changes in the settings, concerning to how the thresholding operation is performed and to the number of gaussians used for outside tissues.

The proposed CT normalization procedure was developed for hybrid PET/CT scanners, since this is the most widely diffuse system for both clinical and research applications. This approach does not require any tracer-specific template to determine the spatial normalization. Notably, while the present procedure was validated using the ^18^F-Florbetaben tracer, it can be adopted as well with other radioligands. This CT-based approach could also be useful for analyzing large retrospective databases where CT, but not MRI, scans are only available. Another important application could be the development of an automated processing pipeline that can aid clinicians in the evaluation of amyloid PET scans. Finally, it should be noted that this procedure was built exclusively using widely available and validated free tools: SPM and the AAL atlas.

5. Conclusions {#s0100}
==============

In this work, we validated an automated spatial normalization method for amyloid PET data, based on the low-dose CT acquired contextually with the PET scan for attenuation correction. This procedure, when compared to the gold-standard MRI-based spatial transformation, showed extremely high levels of concordance in the results of semi-quantification. The procedure is well-suited for both clinical and research applications as well as for radioligands other than amyloid-tracers since it has a simple implementation and is based on validated and widely available tools.
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[^1]: Regional SUVr computed on the whole brain considering the two different spatial normalization pipelines (see text). Values are shown as means, while limits of agreement are computed as: mean(d)-1.96\*sd(d) \| mean(d) + 1.96\*sd(d).

[^2]: Degree of overlap between GM maps normalized using CT-based method, and the reference ones (MRI-based) as a function of the distance needed for the overlap around the reference map (Voxel level, 1 mm, 2 mm, 3 mm).
